Methods to inhibit growth of prostate cancer cells

Details Methods to inhibit growth of prostate cancer cells Methods to inhibit growth of prostate cancer cells

2008-04-22

2008-04-22

Foley, Shanon (Department: 1642)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

C424S178100, C424S133100, C424S139100, C424S141100, C530S387100, C530S387300, C530S388100, C530S388150

Reexamination Certificate

active

10147368

ABSTRACT:
A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.

REFERENCES:
patent: 5530101 (1996-06-01), Queen et al.
patent: 5756309 (1998-05-01), Soppet et al.
patent: 6800746 (2004-10-01), Xu et al.
patent: 2002/0022248 (2002-02-01), Xu et al.
patent: 2002/0192763 (2002-12-01), Xu et al.
patent: 2003/0022237 (2003-01-01), Feder et al.
patent: 2003/0088059 (2003-05-01), Zozulya
patent: 2003/0113798 (2003-06-01), Burmer et al.
patent: 2003/0213004 (2003-11-01), Jakobovits et al.
patent: 1074617 (2001-02-01), None
patent: 1270724 (2003-01-01), None
patent: 2211504 (1989-07-01), None
patent: WO93/17715 (1993-09-01), None
patent: WO-96/39435 (1996-12-01), None
patent: WO9906550 (1999-02-01), None
patent: WO200004149 (2000-01-01), None
patent: WO200020590 (2000-04-01), None
patent: WO-01/27158 (2001-04-01), None
patent: WO200122920 (2001-04-01), None
patent: WO200125272 (2001-04-01), None
patent: WO200125434 (2001-04-01), None
patent: WO200127158 (2001-04-01), None
patent: WO200131014 (2001-05-01), None
patent: WO200134802 (2001-05-01), None
patent: WO200139798 (2001-06-01), None
patent: WO200151633 (2001-07-01), None
patent: WO200157188 (2001-08-01), None
patent: WO200160860 (2001-08-01), None
patent: WO200168805 (2001-09-01), None
patent: WO200173032 (2001-10-01), None
patent: WO200174904 (2001-10-01), None
patent: WO200198526 (2001-12-01), None
patent: WO2002016548 (2002-02-01), None
patent: WO200224726 (2002-03-01), None
patent: WO200228899 (2002-04-01), None
patent: WO200230268 (2002-04-01), None
patent: WO200261087 (2002-08-01), None
patent: WO200289747 (2002-11-01), None
patent: WO200292842 (2002-11-01), None
patent: WO2003009814 (2003-02-01), None
White et al, 2001, Ann Rev Med, 52: 125-145.
Gura (Science, 1997, 278:1041-1042).
Jain (Sci. Am., 1994, 271:58-65).
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).
Hartwell et al (Science, 1997, 278:1064-1068).
Ezzell (J. NIH Res, 1995, 7:46-49).
Spitler (Cancer Biotherapy, 1995, 10:1-3).
Boon (Adv Can Res, 1992, 58:177-210).
Roitt et al, 1998, Immunology, 4th ed, Mosby, London, p. 7.7-7.8.
Holmes (Exp. Opin.Invest. Drugs, 2001, 10(3):511-519).
Bowie et al (Science, 1990, 257 : 1306-1310).
Burgess et al, (Journal of Cell Biology, 1990, 11: 2129-2138).
Lazar et al. Molecular and Cell Biology, 1988, 8: 1247-1252.
Tao. et al. The Journal of Immunology, 1989, 143(8): 2595-2601.
Gillies et al. Human Antibodies and Hybridomas, 1990, 1(1): 47-54).
Roger, I et al, 1988, Bioscience Reports, 8(4): 359-368.
Montesano, R et al, 1996, Intl J Cancer, 69(3): 225-235.
Burmer, GC et al, 1991, Environmental Health perspectives, 93: 27-31.
Busken, C et al, Digestive Disease Week Abstracts and Itinerary Planner, 2003, abstract No. 850.
International Search Report for PCT/US02/15520, mailed on Oct. 20, 2004, 4 pages.
Alberts et al., Molecular Biology of the Cell, 3rd Edition (1994) p. 465.
Bepler et al., Genomics (1999) 55(2):164-175.
Birnbaumer, Cell (1992) 71:1069.
Chang et al., Leukemia (2003) 17:1263-1293.
Craft et al., Cancer Res. (1999) 59:5030-036.
Crystal, Science (1995) 270:404-410.
Deonarain, Expert Opin. Ther. Pat. (1998) 8:53-69.
EMBL Sequence Accession No. A06681.Gcg—Geneseq—D, Jun. 13, 2000 (first entry).
EMBL Sequence Accession No. AF101565, Jan. 29, 1999, Nov. 8, 2000.
Evans et al., Am. J. Obstet. Gynecol. (1994) 171(4):1055-1057.
Fu et al., EMBO Journal (1996) 15:4392-4401.
Greenspan et al., Nature Biotechnology (1999) 7:936-937.
Greulich and Erikson, J. Biol. Chem. (1998) 273:13280.
Harrison, Immunol Series 49:411-464.
Herbert et al., The Dictionary of Immunology, Academic Press, 4thedition, 1995, p. 58.
Hubert et al., Proc. Natl. Acad. Sci. USA (1999) 96(25):14523-14528.
Hummler et al., PNAS USA (1994) 91:5647-5661.
International Search Report for PCT/US02/15520, mailed on Oct. 20, 2004, 4 pages.
Jansen, Pediatric Res. (1995) 37(6):681-686.
Klein et al., Nat. Med. (1997) 3:402.
Lai et al., Clin. Cancer Res. (2000) 6(8):3172-3176.
Liebmann and Bohmer, Curr. Med. Chem. (2000) 7:911.
Malnic et al., Cell (1999) 96:713.
Maniatis et al. (Eds.), Mol. Cloning (1989) Cold Spring Harbor Laboratory, Cold Spring Harbor, p. 17.31.
Maudsley et al., J. Biol. Chem. (2000) 275:9572.
McLean and Hill, Eur. J. of Cancer (1993) 29A:2243-2248.
Miller, Faseb J. (1995) 9:190-199.
Muller et al., MCB (1991) 11:1785.
Nageneseq, EMBL Sequence Accession No. X40518, Jun. 18, 1999 (first entry).
Oya and Schulz, Br. J. Cancer (2000) 83(5):626-631.
Pinto et al., Clin. Cancer Res. (1996) 2(9):1445-1451.
Raming et al., Nature (1993) 361:353.
Raming et al., Receptor Channels (1998) 6:141.
Rampsrch Granli Reports, pp. 2-5, earli, 2002.
Reiter et al., Proc. Natl. Acad. Sci. USA (1998) 95:1735.
Shantz and Pegg, Int. J. of Biochem. and Cell Biol. (1999) 31:107-122.
Sjogren, Immunotechnology (1997) 3(3):161-172.
Su et al., Proc. Natl. Acad. Sci. USA (1996) 93:7252.
Svaren et al., J. Biol. Chem. (2000) 275(49):38524-38531.
Verma, Nature (1997) 389:239-242.
Walter et al., Nat. Genetics (1994) 7:22.
Welch et al., Int. J. Cancer (1989) 43:449-457.
Xu Xin et al., FASEB J. (2001) 15:A313.
Supplementary Partial European Search Report for EP 02 73 6898, mailed on Oct. 4, 2005, 4 pages.
MPSRCH Search Report, us-10-001-469a.2866.rag, p. 10.

Affiliated with

Also associated with

Rating

Methods to inhibit growth of prostate cancer cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods to inhibit growth of prostate cancer cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to inhibit growth of prostate cancer cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3903833